Breath biomarkers for personalized medicine

Personalized Medicine

Volumn 7, Issue 6, 2010, Pages 643-653

  Modak, Anil S ^a  

^a CAMBRIDGE ISOTOPE LABORATORIES INC   (United States)

Author keywords

biomarkers; breath tests; personalized medicine; volatile organic compounds

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; ACETONE; AZATHIOPRINE; BIOLOGICAL MARKER; CETUXIMAB; DEXTROMETHORPHAN C 13; ERLOTINIB; FLUOROURACIL C 13; GEFITINIB; IMATINIB; IRINOTECAN; PANITUMUMAB; PANTOPRAZOLE C 13; RADIOPHARMACEUTICAL AGENT; STABLE ISOTOPE; TRASTUZUMAB; UNCLASSIFIED DRUG; VOLATILE ORGANIC COMPOUND;

BLOOD ANALYSIS; BREAST CANCER; BREATH ANALYSIS; CARBON DIOXIDE BREATHING; CARDIAC GRAFT REJECTION; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; ENDOSCOPY; ENZYME ACTIVITY; HEALTH CARE; HUMAN; IN VIVO STUDY; LUNG CANCER; MEDICINE; MOUTH DISEASE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; QUALITY OF LIFE; RADIOGRAPHY; RESPIRATORY TRACT DISEASE; REVIEW; RISK ASSESSMENT; SURVIVAL;

EID: 78650005708     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.10.61     Document Type: Review

References (107)

1. Gordon SM, Szidon JP, Krotoszynski BK, Gibbons RD, O'Neill NJ: Volatile organic compounds in exhaled air from patients with lung cancer. Clin. Chem. 31, 1278-1282 (1985).
2. O'Neill HJ, Gordon SM, O'Neill MH, Gibbons RD, Szidon JP: A computerized classifcation technique for screening for the presence of breath biomarkers in lung cancer. Clin. Chem. 34, 1613-1618 (1988).
3. Pauling L, Robinson AB, Teranishi R, Cary P: Quantitative analysis of urine vapor and breath by gas-liquid partition chromatography. Proc. Natl Acad. Sci. USA 68, 2374-2384 (1971).
4. Jansson BO, Larsson BTJ: Analysis of organic compounds in human breath by gas chromatography-mass spectrometry laboratory. Clin. Med. 74, 961-966 (1969).
5. Phillips N, Herrera J, Krishnan S, Zain M, Greenberg J, Cataneo R: Variation in volatile organic compounds in the breath of normal humans. J. Chromatogr. B Biomed. Sci. Appl. 729, 75-88 (1999). (Pubitemid 29264111)
6. Modak A: Stable isotope breath tests in clinical medicine: a review. J. Breath Res. 1, 014003(13pp) (2007).
7. Phillips M, Gleeson K, Hughes JM et al.: Volatile organic compounds in breath as markers of lung cancer: a cross-sectional study. Lancet 353, 1930-1933 (1999).
8. Phillips M, Cataneo RN, Cummin AR et al.: Detection of lung cancer with volatile markers in the breath. Chest 123, 2115-2123 (2003). (Pubitemid 36706741)
9. Phillips M, Altorki N, Austin JH et al.: Prediction of lung cancer using volatile biomarkers in breath. Cancer Biomark. 3, 95-109 (2007).
10. Phillips M, Cataneo RN, Ditkoff BA et al.: Prediction of breast cancer using volatile biomarkers in the breath. Breast Cancer Res. Treat. 99, 19-21 (2006).
11. Phillips M, Cataneo R, Condos R et al.: Volatile biomarkers of pulmonary tuberculosis in the breath. Tubercul. (Edinb.) 87, 44-52 (2007). (Pubitemid 44960164)
12. Phillips M, Boehmer J, Cataneo R et al.: Heart Allograft Rejection: Detection with Breath Alkanes in Low Levels (the HARDBALL study). J. Heart Lung Transpl. 23, 701-708 (2004).
13. 13C breath tests in personalized medicine: fction or reality? Exp. Rev. Mol. Diagnos. 9, 805-815 (2009).
14. Silkoff PE, Carlson M, Bourke T, Katial R, Ogren E, Szefer S: The aerocrine exhaled nitric oxide monitoring system NIOX is cleared by the US Food and Drug Administration for monitoring therapy in asthma. Allergy Clin. Immunol. 114, 1241-1256 (2004).
15. 13C-urea breath. Lancet 1, 1174-1177 (1987).
16. Mukhopadhyay R: Don't waste your breath. Researchers are developing breath tests for diagnosing diseases, but how well do they work? Anal. Chem. 76, 273A-276A (2004).
17. Namjou K, Roller CB, McCann PJ: A new laser device to analyze your health. IEEE Circuits Devices Mag. 22, 22-28 (2006
18. Hunt JF, Fang K, Malik R et al.: Endogenous airway acidifcation. Implication for asthma pathophysiology. Am. J. Respir. Crit. Care Med. 161, 694-699 (2000).
19. Corradi M, Folesani G, Andreoli R et al.: Aldehydes and glutathione in exhaled breath condensate of children with asthma exacerbation. Am. J. Respir. Crit. Care Med. 167, 395-399 (2003). (Pubitemid 36216422)
20. Wood LG, Gibson PG, Garg ML: Biomarkers of lipid peroxidation, airway infammation and asthma. Eur. Respir. J. 21, 177-186 (2003).
21. Corradi M, Rubinstein I, Andreoli et al.: Aldehydes in exhaled breath condensate of patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 167, 1380-1386 (2003).
22. Gonzalez-Reche LM, Kucharczyk A, Musiol AK, Kraus T: Determination of N e-(carboxymethyl)lysine in exhaled breath condensate using isotope dilution liquid chromatography/electrospray ionization tandem mass spectrometry Rapid Commun. Mass Spectrom. 20, 2747-2752 (2006). (Pubitemid 44497405)
23. Phillips M, Cataneo RN, Cheema T, Greenberg J: Increased breath biomarkers of oxidative stress in diabetes mellitus. Clin. Chim. Acta 344, 189-194 (2004). (Pubitemid 38626154)
24. Deng C, Zhang J, Yu X, Zhang W, Zhang X: Determination of acetone in human breath by gas chromatography-mass spectrometry and solid-phase micro extraction with on-fber derivatization. J. Chromatogr. B. 810, 269-275 (2004). (Pubitemid 39243314)
25. Phillips M, Cataneo RN, Ditkoff BA et al.: Volatile markers of breast cancer in the breath. Breat J. 9, 184-191 (2003).
26. Phillips M, Cataneo RN, Greenberg J et al.: Effect of age on the breath methylated alkane contour, a display of apparent new markers of oxidative stress. J. Lab. Clin. Med. 136, 243-249 (2000).
27. Poli D, Carbognani P, Corradi M et al.: Exhaled volatile organic compounds in patients with non-small cell lung cancer: cross sectional and nested short-term follow-up study. Respir. Res. 6, 71 (2005).
28. Di Natale C, Macagnano A, Martinelli E et al.: Lung cancer identifcation by the analysis of breath by means of an array of non-selective gas sensors. Biosens. Bioelectron. 18, 1209-1218 (2003
29. Ruzsanyi V, Baumbach JI, Sielemann S, Litterst P, Westhoff M, Freitag L: Detection of human metabolites using multi-capillary columns coupled to ion mobility spectrometers. J. Chromatogr. A 1084, 145-151 (2005).
30. Phillips M, Boehmer JP, Cataneo RN et al.: Prediction of heart transplant rejection with a breath test for markers of oxidative stress. Am. J. Cardiol. 94, 1593-1594 (2004).
31. Sobotka PA, Gupta DK, Lansky DM, Costanzo MR, Zarling EJ: Breath pentane is a marker of acute cardiac allograft rejection. J. Heart Lung Transpl. 13, 224-229 (1994).
32. Lee J, Ngo J, Blake DB et al.: Improved predictive models for plasma glucose estimation from multi-linear regression analysis of exhaled volatile organic compounds. J. Appl. Physiol. 107, 155-160 (2009).
33. Greiter MB, Keck L, Siegmund T et al.: Differences in exhaled gas profles between patients with Type II diabetes and healthy controls. Diabetes Technol. Ther. 12, 455-463 (2010).
34. Lee J, Ngo J, Blake D et al.: Improved predictive models for plasma glucose estimation from multi-linear regression analysis of exhaled volatile organic compounds. J. Appl. Physiol.107, 155-160 (2009).
35. Phillips M, Cataneo RN, Greenberg J, Munawar M, Nachnani S, Samtani S: Pilot study of a breath test for VOCs associated with oral malador evidence of oxidative stress. Oral Dis. 11, 32-34 (2005).
36. Whittle CL, Fakharzadeh S, Eades J, Preti G: Oral malador has been linked to increased risk of cardiovascular disease. Human breath odors and their use in diagnosis. Ann. NY Acad. Sci. 1098, 252-266 (2007).
37. Dalinga JW, Robroeks C, van Berkel J et al.: Volatile organic compounds in exhaled breath as a diagnostic tool for asthma in children. Clin. Exp. Allergy 40, 68-66 (2009).
38. Pijnenburg M, De Jongste J: Exhaled nitric oxide in childhood asthma: a review. Clin. Exp. Allergy 38, 246-259 (2007).
39. Phillips M, Cataneo R, Chaturvedi A et al.: Effect of infuenza vaccination on oxidative stress products in breath. J. Breath Res. 4, 026001 (8pp) (2010).
40. Phillips M, Basa-Dalayc V, Bothamley G: Breath biomarkers of active pulmonary tuberculosis. Tuberculosis 1-7 (2010).
41. Španêl P, Smith D, Holland TA, Al Singary W, Elder JB: Analysis of formaldehyde in the headspace of urine from bladder and prostate cancer patients using selected ion fow tube mass spectrometry. Rapid Commun. Mass Spectrom. 13, 1354-1359 (1999).
42. Fuchs P, Loeseken C, Schubert JK, Miekisch W: Breath gas aldehydes as biomarkers of lung cancer. Int. J. Cancer 126(11), 2663-2670 (2010).
43. Chan HP, Tran V, Lewis C, Thomas P: Markers of oxidative stress in exhaled breath of subjects with lung cancer. Respirology 13, A58 (2008).
44. Chung-man Ho J, Zheng S, Comhair SA, Farver C, Erzurum SC: Differential expression of manganese superoxide dismutase and catalase in lung cancer. Cancer Res. 61, 8578-8585 (2001).
45. Lehtonen ST, Svensk AM, Soini Y et al.: Peroxiredoxins, a novel protein family in lung cancer. Int. J. Cancer 111, 514-521 (2004).
46. Liu CY, Wang CH, Chen TC, Lin HC, Yu CT, Kuo HP: Increased level of exhaled nitric oxide and up-regulation of inducible nitric oxide synthase in patients with primary lung cancer. Br. J. Cancer 78, 534-541 (1998).
47. Carpagnano GE, Spanevello A, Curci C et al.: IL-2, TNF-a, and leptin: local versus systemic concentrations in NSCLC patients. Oncol. Res. 16, 375-381 (2007).
48. Crohns M, Saarelainen S, Laitinen J, Peltonen K, Alho H, Kellokumpu-Lehtinen P: Exhaled pentane as a possible marker for survival and lipid peroxidation during radiotherapy for lung cancer-a pilot study. Free Radical Res. 43, 965-974 (2009).
49. Chen X, Xu F, Wang Y, Pan Y, Lu D, Wang P: A study of the volatile organic compounds exhaled by lung cancer cells in vitro for breath diagnosis. Cancer 110, 835-844 (2007).
50. Sponring A, Filipiaki W, Mikoviny T et al.: Release of volatile organic compounds from the lung cancer cell line NCI-H2087 in vitro. Anticancer Res. 29, 419-426 (2009).
51. Mazzone PJ: Analysis of volatile organic compounds in the exhaled breath for the diagnosis of lung cancer. J. Thorac. Oncol. 3, 774-780 (2008).
52. Mazzone P: Nanomedicine: sniffng out lung cancer. Nat. Nanotechnol. 4, 621-622 (2009).
53. Phillips M, Altorki N, Austin JH et al.: Detection of lung cancer using weighted digital analysis of breath biomarkers. Clin. Chim. Acta. 393(2), 76-84 (2008).
54. Yung T: Is that lung cancer I smell in your breath? UTMJ 87, 122-123 (2010).
55. Bajtarevic A, Ager C, Pienz M et al.: Noninvasive detection of lung cancer by analysis of exhaled breath. BMC Cancer 9, 348 (2009).
56. Feig SA: Screening mammography controversies: resolved, partly resolved, and unresolved. Breast J. 11(Suppl. 1) S3-S6 (2005).
57. Chu D, Lu J: Novel therapies in breast cancer: what is new from ASCO. J. Hematol. Oncol. 1, 16 (2008).
58. Oestreicher N, Lehman CD, Seger DJ, Buist DS White E: The incremental contribution of clinical breast examination to invasive cancer detection in a mammography screening program. AJR Am. J. Roentgenol 184, 428-432 (2005).
59. Baines CJ: Are there downsides to mammography screening? Breast J. 11, S7-S10 (2005).
60. Kasapovic J, Pejic S, Todorovic A, Stojiljkovic V, Pajovic S: Antioxidant status and lipid peroxidation in the blood of breast cancer patients of different ages. Cell Biochem. Funct. 26, 723-730 (2008).
61. Mense SM, Remotti F, Bhan A et al.: Estrogen-induced breast cancer: alterations in breast morphology and oxidative stress as a function of estrogen exposure. Toxicol. Appl. Pharmacol. 232, 78-85 (2008).
62. Hietanen E, Bartsch H, Béréziat JC et al.: 1994 diet and oxidative stress in breast, colon and prostate cancer patients: a case-control study. Eur. J. Clin. Nutr. 48, 575-586 (1994).
63. Kneepkens CM, Ferreira C, Lepage G, Roy CC: The hydrocarbon breath test in the study of lipid peroxidation: principles and practice. Clin. Invest. Med. 15, 163-186 (1992).
64. Phillips M, Cataneo R, Saunders C, Hope P, Schmitt P, Wai J: Volatile biomarkers in the breath of women with breast cancer. J. Breath Res. 4, 026003 (2010).
65. Ulanowska A, Ligor T, Michel M, Buszewski B: Hyphenated and unconventional methods for searching volatile cancer biomarkers. Ecol. Chem. Engineer. 17, 9-22 (2010).
66. Horvath I, Hunt J, Barnes PJ: Exhaled breath condensate: methodological recommendations and unresolved questions. Eur. Respir. J. 26, 523-548 (2005).
67. Machado RF, Laskowski D, Deffenderfer O et al.: Detection of lung cancer by sensor array analyses of exhaled breath. Am. J. Respir. Crit. Care Med. 171, 1286-1291 (2005).
68. Dragonieri S, Annema JT, Schot R et al.: An electronic nose in the detection of lung cancer. Am. J. Respir. Crit. Care Med. 175, A330 (2007).
69. Corradi M, Poli D, Selis L et al.: Volatile hydrocarbons in exhaled air: preliminary data on the characteristic profle associated with lung tumors. G. Ital. Med. Lav. Ergon. 25, 59-60 (2003).
70. Baumbach JI: Process analysis using ion mobility spectrometry. Anal. BioAnal. Chem. 384, 1059-1070 (2006).
71. Smith D, Španêl P: Selected ion fow tube mass spectrometry (SIFT-MS) for on-line trace gas analysis. Mass Spectrom. Rev. 24(5), 661-700 (2005).
72. Amann A, Smith D (Eds): Breath Analysis for Clinical Diagnosis and Therapeutic Monitoring World Scientifc, Singapore (2005).
73. Peng G, Hakim M, Broza Y et al.: Detection of lung, breast, colorectal, and prostate cancers from exhaled breath using a single array of nanosensors. Br. J. Cancer 103, 542-551 (2010).
74. Peng G, Tisch U, Haick H: Detection of nonpolar molecules by means of carrier scattering in random networks of carbon nanotubes: toward diagnosis of diseases via breath samples. Nano Lett. 9, 1362-1368 (2009).
75. Peng G, Tisch U, Adams O et al.: Diagnosing lung cancer in exhaled breath using gold nanoparticles. Nat. Nanotechnol. 4, 669-673 (2009).
76. Peng G, Trock E, Haick H: Detecting simulated patterns of lung cancer biomarkers by random network of single-walled carbon nanotubes coated with nonpolymeric organic materials. Nano Lett. 8, 3631-3635 (2008).
77. Martin AN, Farquar GR, Jones AD, Frank M: Human breath analysis: methods for sample collection and reduction of localized background effects. Anal. BioAnal. Chem. 396, 739-750 (2009).
78. Smith D, Spanel P, Sule-Suso J: Advantages of breath testing for the early diagnosis of lung cancer. Expert Rev. Mol. Diagn. 10(3), 255-257 (2010).
79. Buszewski B, Martyna Kesy M, Ligor T, Amann A: Human exhaled air analytics: biomarkers of diseases. Biomed. Chromatogr. 21, 553-566 (2007).
80. Alfrevic A, Pirmohamed M: Adverse drug reactions and pharmacogenomics: recent advances. Per. Med. 5, 11-23 (2008).
81. Grant R, Wilkinson GR: Drug metabolism and variability among patients in drug response. N. Engl. J. Med. 352, 2211-2221 (2005).
82. Raida M, Schwabe W, Häusler P: Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5́-splice donor site of intron 14 in patients with severe 5-fuorouracil (5-FU)-related toxicity compared with controls. Clin. Cancer Res. 7, 2832-2839 (2001).
83. Meta-Analysis Group: Toxicity of fuorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Cancer J. Clin. Oncol. 16, 3537-3541 (1998).
84. Johnson MR, Diasio RB: Importance of dihydropyrimidine dehydrogenase (DPD) defciency in patients exhibiting toxicity following treatment with 5-fuorouracil. Adv. Enzyme Regul. 41, 151-157 (2001).
85. Van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH: High prevalence of the IVS14 +1G→A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fuorouracil-associated toxicity. Pharmacogenetics 12, 555-558 (2002).
86. Daher GC, Harris BE, Diasio RB: Metabolism of pyrimidine analogues and their nucleosides. Pharmacol. Ther. 48, 189-222 (1990).
87. Diasio RB, Beavers TL, Carpenter JT: Familial defciency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fuorouracil-induced toxicity. J. Clin. Invest. 81, 47-51 (1988).
88. Diasio RB, Harris BE: Clinical pharmacology of 5-fuorouracil. Clin. Pharmacokinet. 16, 215-237 (1989).
89. Heggie G, Sommadossi J, Cross D, Huster W, Diasio R: Clinical pharmacokinetics of 5-fuorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 47, 2203-2206 (1987).
90. Bygrave H, Geh J, Jani Y, Glynne-Jones R: Neurological complications of 5-fuorouracil chemotherapy: case report and review of the literature. Clin. Oncol. 10, 334-336 (1998).
91. Fleming R, Milano G, Gaspard M et al.: Dihydropyrimidine dehydrogenase activity in cancer patients. Eur. J. Cancer A 29, 740-744 (1993).
92. Harris B, Carpenter J, Diasio R: Severe 5-fuorouracil toxicity secondary to dihydropyrimidine dehydrogenase defciency. A potentially more common pharmacogenetic syndrome. Cancer 68, 499-501 (1991).
93. Johnson M, Hageboutros A, Wang K, High L, Smith J, Diasio RB: Life-threatening toxicity in a dihydropyrimidine dehydrogenase-defcient patient after treatment with topical 5-fuorouracil. Clin. Cancer Res. 5, 2006-2011 (1999).
94. Lu Z, Zhang R, Diasio R: Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identifed defcient patients, and clinical implication in 5-fuorouracil chemotherapy. Cancer Res. 53, 5433-5438 (1993).
95. Milano G, Etienne M, Pierrefte V, Barberi-Heyob M, Deporte-Fety R, Renee N: Dihydropyrimidine dehydrogenase defciency and fuorouracil-related toxicity. Br. J. Cancer 79, 627-630 (1999).
96. Morrison G, Bastian A, Dela Rosa T, Diasio R, Takimoto C: Dihydropyrimidine dehydrogenase defciency: a pharmacogenetic defect causing severe adverse reactions to 5-fuorouracil-based chemotherapy. Oncol. Nurs. Forum 24, 83-88 (1997).
97. Schneider H, Becker H: Dehydropyrimidine dehydrogenase defciency in a cancer patient undergoing 5-fuorouracil chemotherapy. Anticancer Res. 24, 1091-1092 (2004).
98. Takimoto CH, Lu ZH, Zhang R et al.: Severe neurotoxicity following 5-fuorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase defciency. Clin. Cancer Res. 2, 477-481 (1996).
99. van Kuilenburg AB, Meinsma R, Zonnenberg BA et al.: Dihydropyrimidinase defciency and severe 5-fuorouracil toxicity. Clin. Cancer Res. 9, 4363-4367 (2003).
100. Mattison L, Ezzeldin H, Carpenter M, Johnson M, Diasio R: Rapid identifcation of dihydropyrimidine dehydrogenase defciency by using a novel 2-13C-uracil breath test. Clin. Can. Res. 10, 2652-2659 (2004).
101. Mattison L, Fourie J, Renee A et al.: Racial differences in dihydropyrimidine dehydrogenase activity: increased prevalence of DPD defciency in African Americans compared to caucasians. Clin. Can. Res. 12, 5491-5495 (2006).
102. Hayashi K, Owaki T, Sumi S et al.: Usefulness of uracil loading test for detecting 5-fuorouracil metabolic enzyme defciencies in humans. Int. J. Clin. Oncol. 5(5), 171-173 (2000).
103. Ingelman-Sundberg M: Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol. Sci. 25, 193-200 (2004).
104. 13C]-DM breath test to assess CYP2D6 phenotype. J. Clin. Pharm. 48, 2041-2051 (2008).
105. 13C]-pantoprazole breath test. JPET 329, 297-305 (2009).
106. 13C] pantoprazole breath test as a predictor of the anti-platelet function of clopidogrel. Eur. J. Clin. Pharmacol. 66, 457-463 (2010).
107. 13C]-pantoprazole breath test to predict CYP2C19 phenotype and effcacy of a proton pump inhibitor, lansoprazole. Aliment. Pharmacol. Ther. 30, 294-300 (2009).